MannKind Stock Price, News & Analysis (NASDAQ:MNKD)

$2.49 -0.02 (-0.80 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$2.49
Today's Range$2.48 - $2.56
52-Week Range$0.67 - $6.96
Volume1.45 million shs
Average Volume1.89 million shs
Market Capitalization$286.04 million
P/E Ratio-9.22
Dividend YieldN/A
Beta3.08

About MannKind (NASDAQ:MNKD)

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone+1-818-6615000

Debt

Debt-to-Equity Ratio-0.43%
Current Ratio0.31%
Quick Ratio0.28%

Price-To-Earnings

Trailing P/E Ratio-9.22222222222222
Forward P/E Ratio-2.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.76 million
Price / Sales1.69
Cash Flow$0.61 per share
Price / Cash4.09
Book Value($1.92) per share
Price / Book-1.30

Profitability

Trailing EPS($0.27)
Net Income$125.66 million
Net Margins-155.83%
Return on Equity-24.93%
Return on Assets-130.34%

Miscellaneous

Employees153
Outstanding Shares118,870,000

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.11. The biopharmaceutical company earned $2.04 million during the quarter, compared to the consensus estimate of $2.56 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The business's quarterly revenue was down 98.7% on a year-over-year basis. During the same period last year, the firm earned $1.30 EPS. View MannKind's Earnings History.

When will MannKind make its next earnings announcement?

MannKind is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for MannKind.

Where is MannKind's stock going? Where will MannKind's stock price be in 2018?

4 brokers have issued twelve-month target prices for MannKind's shares. Their predictions range from $0.83 to $1.00. On average, they anticipate MannKind's share price to reach $0.92 in the next twelve months. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:

  • 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (1/10/2018)
  • 2. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)

Are investors shorting MannKind?

MannKind saw a increase in short interest during the month of December. As of December 29th, there was short interest totalling 32,495,394 shares, an increase of 2.7% from the December 15th total of 31,632,163 shares. Based on an average trading volume of 3,389,713 shares, the short-interest ratio is presently 9.6 days. Approximately 32.6% of the shares of the stock are sold short.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:

  • Kent Kresa, Chairman of the Board (Age 78)
  • Michael E. Castagna Pharm.D., Chief Executive Officer, Director (Age 40)
  • Rosabel R. Alinaya, Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer (Age 56)
  • Steven B Binder, Chief Financial Officer, Principal Accounting Officer (Age 54)
  • Linda Adreveno, Senior Vice President - Human Resources (Age 60)
  • Joseph Kocinsky, Chief Technology Officer, Corporate Vice President (Age 52)
  • David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary (Age 49)
  • Patrick McCauley J.D., Chief Commercial Officer
  • Stuart A. Tross Ph.D., Chief People Officer (Age 49)
  • James Samuel Shannon M.D., Director (Age 60)

Who owns MannKind stock?

MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.16%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.

Who bought MannKind stock? Who is buying MannKind stock?

MannKind's stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MannKind stock can currently be purchased for approximately $2.49.

How big of a company is MannKind?

MannKind has a market capitalization of $286.04 million and generates $174.76 million in revenue each year. The biopharmaceutical company earns $125.66 million in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 153 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 Russell Ranch Rd Ste 301, WESTLAKE VILLAGE, CA 91362-7378, United States. The biopharmaceutical company can be reached via phone at +1-818-6615000 or via email at [email protected]


MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  593
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MannKind (NASDAQ:MNKD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldSell
Consensus Rating Score: 1.751.752.001.00
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $0.92$0.92$0.92$0.92
Price Target Upside: 71.85% downside71.85% downside82.83% downside19.03% downside

MannKind (NASDAQ:MNKD) Consensus Price Target History

Price Target History for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
11/1/2017Maxim GroupReiterated RatingBuy -> HoldN/AView Rating Details
5/22/2017JPMorgan Chase & Co.Reiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
5/8/2017S&P Equity ResearchLower Price Target$1.04 -> $0.83HighView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs GroupReiterated RatingSellN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

MannKind (NASDAQ:MNKD) Earnings History and Estimates Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/7/2017Q3 2017($0.20)($0.31)$2.56 million$2.04 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.25)($0.35)$2.75 million$2.16 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
10/29/2010Q3 2010($1.95)($2.00)ViewN/AView Earnings Details
8/2/2010Q2 2010($2.00)($1.87)ViewN/AView Earnings Details
4/30/2010Q1 2010($2.20)($1.98)ViewN/AView Earnings Details
2/1/2010Q4 2009($2.05)($2.64)ViewN/AView Earnings Details
11/2/2009Q3 2009($2.45)($2.10)ViewN/AView Earnings Details
8/3/2009Q2 2009($2.80)($2.72)ViewN/AView Earnings Details
5/4/2009Q1 2009($3.25)($2.91)ViewN/AView Earnings Details
2/17/2009Q4 2008($3.20)($4.10)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.00)($3.37)ViewN/AView Earnings Details
8/11/2008Q2 2008($3.70)($3.94)ViewN/AView Earnings Details
5/5/2008Q1 2008($3.90)($3.52)ViewN/AView Earnings Details
3/4/2008Q4 2007($3.90)($3.77)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MannKind (NASDAQ:MNKD) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS

Dividends

Dividend History for MannKind (NASDAQ:MNKD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 12.10%
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2017Stuart A TrossVPBuy39,840$2.52$100,396.8059,840View SEC Filing  
12/20/2017Michael CastagnaCEOBuy8,000$2.29$18,320.0035,532View SEC Filing  
10/13/2017Kent KresaDirectorBuy166,600$6.00$999,600.00View SEC Filing  
8/10/2017Raymond W UrbanskiCMOSell296$1.15$340.402,924View SEC Filing  
6/30/2017Rosabel Realica AlinayaSVPBuy2,000$1.23$2,460.0030,091View SEC Filing  
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60403,085View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22140,456View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00212,500View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00195,000View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00180,000View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00397,996View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.0075,000View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.0050,000View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50139,024View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56158,858View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00139,450View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17729,685View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00139,450View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.0083,752View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57171,504View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00112,756View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.1240,082View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00136,016View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MannKind (NASDAQ MNKD) News Headlines

Source:
DateHeadline
The Simple Reason Why I Won't Buy MannKind Corporation StockThe Simple Reason Why I Won't Buy MannKind Corporation Stock
finance.yahoo.com - January 18 at 10:40 AM
The Simple Reason Why I Wont Buy MannKind Corporation StockThe Simple Reason Why I Won't Buy MannKind Corporation Stock
www.fool.com - January 18 at 10:28 AM
MannKind Co. (MNKD) Receives Consensus Rating of "Hold" from BrokeragesMannKind Co. (MNKD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 18 at 1:08 AM
MannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor ConferenceMannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference
finance.yahoo.com - January 16 at 9:48 AM
Financial Survey: CytomX Therapeutics (CTMX) and MannKind (MNKD)Financial Survey: CytomX Therapeutics (CTMX) and MannKind (MNKD)
www.americanbankingnews.com - January 15 at 1:10 AM
MannKind Co. (MNKD) Sees Large Increase in Short InterestMannKind Co. (MNKD) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 12 at 3:14 AM
These Two Updates Caused MannKinds Stock to Plunge 25.9% in December - Motley FoolThese Two Updates Caused MannKind's Stock to Plunge 25.9% in December - Motley Fool
www.fool.com - January 5 at 9:53 AM
These Two Updates Caused MannKind's Stock to Plunge 25.9% in DecemberThese Two Updates Caused MannKind's Stock to Plunge 25.9% in December
finance.yahoo.com - January 5 at 9:53 AM
These Two Updates Caused MannKinds Stock to Plunge 25.9% in December These Two Updates Caused MannKind's Stock to Plunge 25.9% in December
www.fool.com - January 5 at 9:51 AM
Why MannKind Corporation Jumped Higher TodayWhy MannKind Corporation Jumped Higher Today
finance.yahoo.com - January 2 at 6:11 PM
MannKind (MNKD) Raised to "Sell" at ValuEngineMannKind (MNKD) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - December 30 at 11:16 PM
MannKind: Still Looking Weak - Seeking AlphaMannKind: Still Looking Weak - Seeking Alpha
seekingalpha.com - December 29 at 10:18 AM
MannKind CEO, Exec Bought Stock in December - BarronsMannKind CEO, Exec Bought Stock in December - Barron's
www.barrons.com - December 28 at 6:22 AM
Do Options Traders Know Something About MannKind Corp (MNKD) Stock We Don't?Do Options Traders Know Something About MannKind Corp (MNKD) Stock We Don't?
finance.yahoo.com - December 28 at 6:22 AM
[$$] MannKind CEO, Exec Bought Stock in December[$$] MannKind CEO, Exec Bought Stock in December
finance.yahoo.com - December 28 at 6:22 AM
ETFs with exposure to MannKind Corp. : December 25, 2017ETFs with exposure to MannKind Corp. : December 25, 2017
finance.yahoo.com - December 25 at 6:51 PM
MannKind - Scripts, Deerfield, And Insider Buys - Seeking AlphaMannKind - Scripts, Deerfield, And Insider Buys - Seeking Alpha
seekingalpha.com - December 24 at 3:49 AM
MannKind Co. (MNKD) Given Average Recommendation of "Sell" by BrokeragesMannKind Co. (MNKD) Given Average Recommendation of "Sell" by Brokerages
www.americanbankingnews.com - December 24 at 1:31 AM
MannKind (MNKD) Downgraded by BidaskClub to "Sell"MannKind (MNKD) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - December 22 at 7:32 PM
Stuart A. Tross Purchases 39,840 Shares of MannKind Co. (MNKD) StockStuart A. Tross Purchases 39,840 Shares of MannKind Co. (MNKD) Stock
www.americanbankingnews.com - December 21 at 11:36 PM
Insider Buying: MannKind Co. (MNKD) CEO Buys 8,000 Shares of StockInsider Buying: MannKind Co. (MNKD) CEO Buys 8,000 Shares of Stock
www.americanbankingnews.com - December 20 at 6:28 PM
Why Red Hat, MannKind, and Navistar International Slumped TodayWhy Red Hat, MannKind, and Navistar International Slumped Today
finance.yahoo.com - December 20 at 5:04 PM
MannKind (MNKD) Lowered to Sell at Zacks Investment ResearchMannKind (MNKD) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 17 at 1:38 PM
ETFs with exposure to MannKind Corp. : December 14, 2017ETFs with exposure to MannKind Corp. : December 14, 2017
finance.yahoo.com - December 14 at 5:37 PM
Why MannKind Corporation Dipped 4.8% in November - Motley FoolWhy MannKind Corporation Dipped 4.8% in November - Motley Fool
www.fool.com - December 7 at 5:30 PM
Why MannKind Corporation Dipped 4.8% in NovemberWhy MannKind Corporation Dipped 4.8% in November
finance.yahoo.com - December 5 at 5:02 PM
MannKind (MNKD) Rating Lowered to Hold at BidaskClubMannKind (MNKD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 2 at 12:40 PM
MannKind Corporation (MNKD) Given Average Rating of "Hold" by BrokeragesMannKind Corporation (MNKD) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 29 at 1:38 AM
Implied Volatility Surging for MannKind (MNKD) Stock OptionsImplied Volatility Surging for MannKind (MNKD) Stock Options
finance.yahoo.com - November 27 at 4:55 PM
ETFs with exposure to MannKind Corp. : November 27, 2017ETFs with exposure to MannKind Corp. : November 27, 2017
finance.yahoo.com - November 27 at 4:55 PM
MannKind Corporation (MNKD) Downgraded by ValuEngine to "Strong Sell"MannKind Corporation (MNKD) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - November 26 at 12:56 PM
MannKind: Afrezza Scripts And Revenue Rising - Is It Enough? - Seeking AlphaMannKind: Afrezza Scripts And Revenue Rising - Is It Enough? - Seeking Alpha
seekingalpha.com - November 25 at 9:33 AM
An Integrated BioSci Research On MannKind Corporation: How To Unlock Value? - Seeking AlphaAn Integrated BioSci Research On MannKind Corporation: How To Unlock Value? - Seeking Alpha
seekingalpha.com - November 23 at 6:32 AM
MannKind Corp. :MNKD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017MannKind Corp. :MNKD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 22 at 5:24 AM
MannKind CEO Michael Castagna on Whats Ahead for the BiotechMannKind CEO Michael Castagna on What's Ahead for the Biotech
www.fool.com - November 21 at 7:06 AM
MannKind CEO Michael Castagna on What's Ahead for the BiotechMannKind CEO Michael Castagna on What's Ahead for the Biotech
finance.yahoo.com - November 21 at 7:06 AM
MannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches - Seeking AlphaMannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches - Seeking Alpha
seekingalpha.com - November 19 at 8:08 AM
MannKind: Insider Trading, Short Interest, And Catalysts, Oh My - Seeking AlphaMannKind: Insider Trading, Short Interest, And Catalysts, Oh My - Seeking Alpha
seekingalpha.com - November 17 at 5:29 PM
MannKind Corp. – Value Analysis (NASDAQ:MNKD) : November 15, 2017MannKind Corp. – Value Analysis (NASDAQ:MNKD) : November 15, 2017
finance.yahoo.com - November 17 at 5:29 PM
MannKind Corp. breached its 50 day moving average in a Bearish Manner : MNKD-US : November 14, 2017MannKind Corp. breached its 50 day moving average in a Bearish Manner : MNKD-US : November 14, 2017
finance.yahoo.com - November 15 at 6:26 AM
Analyzing MannKind Corporation (MNKD) and Its PeersAnalyzing MannKind Corporation (MNKD) and Its Peers
www.americanbankingnews.com - November 14 at 5:18 AM
Does MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves QuestionsDoes MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves Questions
finance.yahoo.com - November 12 at 7:44 AM
MannKind Has Much Room for Upside in Diabetes Market: Here’s WhyMannKind Has Much Room for Upside in Diabetes Market: Here’s Why
finance.yahoo.com - November 12 at 7:44 AM
MannKind Corporation (MNKD) Sees Large Increase in Short InterestMannKind Corporation (MNKD) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 11 at 1:48 AM
EARNINGS SUMMARY: Details of MannKind Corp. Q3 Earnings ReportEARNINGS SUMMARY: Details of MannKind Corp. Q3 Earnings Report
www.rttnews.com - November 9 at 1:54 AM
Heres Why MannKind Corporation Is Sinking - Motley FoolHere's Why MannKind Corporation Is Sinking - Motley Fool
www.fool.com - November 8 at 8:53 PM
5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update
finance.yahoo.com - November 8 at 8:53 PM
5 Things You Dont Want to Overlook in MannKind Corporations Q3 Update5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update
www.fool.com - November 8 at 8:49 PM
MannKinds (MNKD) CEO Michael Castagna on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaMannKind's (MNKD) CEO Michael Castagna on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 3:48 PM
MannKind Corporation Reports 2017 Third Quarter Financial Results - GlobeNewswire (press release)MannKind Corporation Reports 2017 Third Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 3:48 PM

SEC Filings

MannKind (NASDAQ:MNKD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MannKind (NASDAQ MNKD) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.